Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Fujikura Exercises Option to License Cellmid’s Diagnostics

Published: Monday, July 22, 2013
Last Updated: Monday, July 22, 2013
Bookmark and Share
License is expected to be signed for multiple cancer diagnostic products.

Cellmid Limited has received confirmation that Fujikura Kasei Co Ltd (Fujikura) will exercise its Option to license the midkine (MK) diagnostic technology by paying the requisite JPY40 million (AUD 440,000) Milestone Fee.

Under the terms of the Option to License agreement, which was signed between the companies in February 2013, Cellmid supplied Fujikura with its proprietary anti-midkine diagnostic antibodies for validation on Fujikura’s latex platform.

Proceeding to a license agreement was conditional on Fujikura reaching accuracy of 500 picogram/ml midkine on its latex diagnostic platform using Cellmid’s antibodies.

Fujikura has since completed this milestone, reached the required accuracy and advised Cellmid of its intention to exercise its Option.

The parties will now proceed to a supply and license agreement for the development and marketing of multiple cancer diagnostic products using Fujikura’s latex assay with Cellmid’s MK antibodies.

The license between the parties is expected to grant exclusive rights to Fujikura to use Cellmid’s proprietary antibodies for latex based tests.

In return, Fujikura will pay royalties on products sold. Product development and marketing costs will be borne by Fujikura.

A latex based test with a 500 picogram/ml accuracy can be used reliably to identify individuals with elevated midkine levels. This in turn is expected to lead to the development of a number of cancer diagnostic products.

Cellmid will support Fujikura’s regulatory and product development programmes with its MK diagnostic expertise.

Cellmid has a highly accurate MK-ELISA already, however a latex based assay will be suitable for commercial products, as it is widely used and accepted in pathology laboratories. It is also preferred as it can easily be automated, reducing processing costs.

Fujikura Kasei is one of the largest suppliers of latex particles for the medical diagnostics industry in Japan. While traditionally servicing other industries with polymers and resins, Fujikura has been actively expanding into medical diagnostics.

“We are pleased with the progress of our project with Cellmid and looking forward to developing and marketing a number of cancer diagnostic products using midkine as a key marker on our platform” said Fujikura’s Head of Medical Project Division, Dr Hideyuki Kuroda.

Cellmid CEO Maria Halasz said she was impressed by Fujikura’s technical skills in developing a latex based midkine test.

“With Fujikura’s strong focus on building market share in proprietary cancer tests our MK diagnostic technology is in good hands” she said.

Midkine has been extensively validated as an early marker for a range of cancers and has been shown to be useful in prognosis and disease management.

A license agreement involving MK for the early diagnosis, prognosis and disease monitoring of lung cancer was signed in 2009 with Celera-Quest, and for bladder cancer in 2010 with Pacific Edge Biotechnology.

A license with Fujikura Kasei involving multiple cancer indications further validates the Company’s technology, including the quality of its reagents.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos